AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

54
A picture shows British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England, on May 8, 2014. British drugmaker AstraZeneca said it was targeting annual revenues of more than $45 billion (32 billion euros) by 2023, upping its defence against a takeover bid from US rival Pfizer. AFP PHOTO/ANDREW YATES (Photo credit should read ANDREW YATES/AFP/Getty Images)

British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel’s consent in April.

http://feeds.reuters.com/~r/reuters/healthNews/~3/yTWc1bT5Fzg/astrazenecas-lynparza-gets-eu-nod-as-first-line-ovarian-cancer-maintenance-treatment-idUSKCN1TJ0HS

- Advertisement -